Short Interest in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Expands By 10.3%

Enliven Therapeutics, Inc. (NASDAQ:ELVN) saw a significant increase in short interest in September. As of September 30th, there was short interest totalling 6,100,000 shares, an increase of 10.3% from the September 15th total of 5,530,000 shares. Approximately 21.1% of the shares of the company are short sold. Based on an average trading volume of 241,600 shares, the days-to-cover ratio is currently 25.2 days.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $37.00 target price on shares of Enliven Therapeutics in a research report on Tuesday, October 1st.

Enliven Therapeutics Price Performance

Enliven Therapeutics stock traded down $0.10 during midday trading on Thursday, reaching $28.02. The company had a trading volume of 115,367 shares, compared to its average volume of 261,112. Enliven Therapeutics has a 12-month low of $9.80 and a 12-month high of $28.62. The company has a market capitalization of $1.32 billion, a P/E ratio of -14.52 and a beta of 1.10. The firm’s fifty day simple moving average is $23.80 and its 200-day simple moving average is $22.54.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.17. On average, analysts expect that Enliven Therapeutics will post -1.98 EPS for the current fiscal year.

Insider Activity at Enliven Therapeutics

In related news, CEO Samuel Kintz sold 12,000 shares of the business’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $24.92, for a total value of $299,040.00. Following the completion of the transaction, the chief executive officer now directly owns 1,063,525 shares in the company, valued at $26,503,043. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CEO Samuel Kintz sold 12,000 shares of the firm’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $24.92, for a total transaction of $299,040.00. Following the sale, the chief executive officer now directly owns 1,063,525 shares in the company, valued at $26,503,043. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $26.68, for a total value of $140,070.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 180,409 shares of company stock worth $4,800,526. 29.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. First Turn Management LLC acquired a new position in shares of Enliven Therapeutics during the 2nd quarter worth approximately $9,657,000. Janus Henderson Group PLC lifted its position in Enliven Therapeutics by 74.8% during the first quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock worth $12,604,000 after buying an additional 305,397 shares in the last quarter. Marshall Wace LLP acquired a new position in Enliven Therapeutics during the second quarter worth $4,489,000. Baker BROS. Advisors LP purchased a new stake in Enliven Therapeutics in the 1st quarter valued at $2,020,000. Finally, Nicholas Investment Partners LP acquired a new stake in shares of Enliven Therapeutics in the 2nd quarter worth $1,310,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.